

**The Twelfth
Jack Peter Green Lectureship**
In
PHARMACOLOGICAL SCIENCES

George D. Yancopoulos, MD, PhD

President and Chief Scientific Officer
Regeneron Pharmaceuticals, Inc.

“Building a Better Biotech:
The Story of Regeneron”

Thursday, October 11, 2018
11:00 am

Davis Auditorium
Hess Center for Science and Medicine
2nd Floor
1470 Madison Avenue
New York, NY 10029

Reception to follow the lecture



Department of Pharmacological Sciences

Icahn School of Medicine at Mount Sinai
One Gustave L. Levy Place
1425 Madison Avenue
New York, New York 10029
Tel. 212-659-8647

**The Twelfth
Jack Peter Green
Lectureship**
in Pharmacological
Sciences





Jack Peter Green, MD, PhD
(1925 – 2007)

Jack Peter Green, MD, PhD, was Professor Emeritus of Pharmacology and Biological Chemistry at the Icahn School of Medicine at Mount Sinai (ISMMS). He received both his PhD and MD degrees from Yale University and began his academic career at Yale as Assistant Professor of Pharmacology. Following a brief tenure at Cornell University Medical College, he was appointed Professor of Pharmacology, and founding Chairman of the Department of Pharmacology at ISMMS in 1968. In a few short years, he built a department of international renown. Dr. Green's research interests were centered on the biology of histamine and he was an early proponent of histamine, and its metabolites, as central nervous system neurotransmitters and neuromodulators. In recognition of this work he was one of only seven scientists worldwide awarded the highest honor bestowed by the European Histamine Research Society. Dr. Green was also one of the first to apply quantum mechanical techniques to the study of drug action.



George D. Yancopoulos, MD, PhD

George Yancopoulos, MD, PhD, became Regeneron's Scientific Founder and Chief Scientific Officer in 1989, alongside Founder and Chief Executive Officer, Leonard Schleifer, MD, PhD. Dr. Yancopoulos currently also serves as President of Regeneron. After graduating as valedictorian at both Bronx High and Columbia University, he received his MD and PhD in Biochemistry and Molecular Biophysics from Columbia University. In the 1990s, Dr. Yancopoulos was the 11th most highly cited scientist in the world, and in 2004 he was elected to both the National Academy of Sciences and the American Academy of Sciences.

Dr. Yancopoulos, together with key members of his team, is a principal inventor and developer of Regeneron's six FDA-approved medicines, including EYLEA® (afibercept) Injection, DUPIXENT® (dupilumab) Injection and PRALUENT® (alirocumab) Injection. He is also an inventor of Regeneron's foundational technologies for target and drug development, such as its proprietary TRAP technology, VelociGene® and VelocImmune®. In addition to the approved medicines, these technologies have produced Regeneron's robust pipeline of fully human antibodies targeting asthma, allergic disease, pain, cancer, infectious diseases, rare diseases and more. Dr. Yancopoulos and his team are responsible for continual innovations in the drug discovery and development process, such as the Regeneron Genetics Center, a world-leading human genetics effort that has already sequenced exomes from over 300,000 people.

In Honor of
Jack Peter Green

Scientist, scholar, teacher, physician

-
- 2002 Barry S. Collier, MD
The Rockefeller University
 - 2003 Leroy Hood, MD
Institute for Systems Biology
 - 2004 Anthony James Pawson, PhD
University of Toronto
 - 2005 C. Ronald Kahn, MD
Harvard Medical School
 - 2007 Bert W. O'Malley, MD
Baylor College of Medicine
 - 2008 Susan Band Horwitz, PhD
Institute for Systems Biology
 - 2010 Mary V. Relling, PharmD
St. Jude Children's Research Hospital
 - 2011 Harry C. Dietz, MD
Johns Hopkins University School of Medicine
 - 2012 Garret Fitzgerald, PhD
University of Pennsylvania School of Medicine
 - 2013 Susan Amara, PhD
National Institute of Mental Health
 - 2017 David Julius, PhD
University of California, San Francisco